Headlines about REDHILL BIOPHAR/S (NASDAQ:RDHL) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. REDHILL BIOPHAR/S earned a news impact score of 0.05 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.380604769786 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Critical Review: Chiasma (CHMA) & REDHILL BIOPHAR/S (RDHL) (americanbankingnews.com)
- REDHILL BIOPHAR/S (RDHL) Expected to Post Quarterly Sales of $2.77 Million (americanbankingnews.com)
- RedHill Biopharma (RDHL) Prices 4.17 Million Share Underwritten Offering at $6/ADS (streetinsider.com)
- -$0.47 Earnings Per Share Expected for REDHILL BIOPHAR/S (RDHL) This Quarter (americanbankingnews.com)
- RedHill Biopharma Announces Pricing of $25 Million Underwritten Offering (finance.yahoo.com)
Several research firms have recently weighed in on RDHL. ValuEngine raised shares of REDHILL BIOPHAR/S from a “sell” rating to a “hold” rating in a report on Friday, June 29th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of REDHILL BIOPHAR/S in a report on Monday, July 2nd. LADENBURG THALM/SH SH began coverage on shares of REDHILL BIOPHAR/S in a report on Monday, June 25th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Zacks Investment Research raised shares of REDHILL BIOPHAR/S from a “hold” rating to a “buy” rating and set a $6.75 price target on the stock in a report on Saturday, May 12th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $19.96.
About REDHILL BIOPHAR/S
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.
Featured Story: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.